US Application No.: 09/853,193 Filing Date: May 11, 2001

Attorney Docket No.: 6296.204-US Page 4 of 4

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith.

Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: May 6, 2008 /Richard W. Bork, Reg. No. 36,459/

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Inc. Customer Number 23650 (609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE